0145 First safety data from a randomised phase III trial comparing adjuvant epirubicin–cyclophosphamide → docetaxel (EC → T) vs ET → capecitabine (X) in N+ operable breast cancer (BC)

✍ Scribed by M. Martín; A. Lluch; A. Ruiz-Simón; N. Ribelles; M. Ruiz-Borrego; A. Rodríguez-Lescure; M. Muñoz; M. Ramos; S. González; M. Margelí

• Book ID: 114316282
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 56 KB
• Volume: 18
• Category: Article
• ISSN: 0960-9776
• DOI: 10.1016/s0960-9776(09)70176-6